Clinical trials: No Reflow Phenomenon
Myocardial Infarction, Percutaneous Coronary Intervention
Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
The purpose of this study is to determine whether intracoronary selective thrombolysis are more effective than tirofiban on the coronary flow during primary percutaneous coronary intervention for the acute myocardial infarction.
- Conditions
- Myocardial Infarction, Percutaneous Coronary Intervention, Thrombolytic Therapy
- Trial name
- ERUPTION (NCT02131220)
- Testing
- Prourokinase, Tirofiban, normal saline
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Fudan University
No-Reflow Phenomenon
Intracoronary Tirofiban on No-Reflow Phenomena
The goal of this study was to evaluate the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with STEMI and occurrence of no-reflow phenomenon undergoing primary percutaneous coronary…
- Trial name
- NCT02054000
- Testing
- Tirofiban
- Where
- Turkey (Türkiye)
- Volunteers
- 162 people
- Sponsor
- TC Erciyes University
Coronary Artery Disease, Coronary Artery Ectasia
Evaluation of Emotional Status and Coronary Flow Characteristics by TIMI Frame Count Method
This study evaluates the effects of emotional status on coronary flow in patients undergoing elective coronary angiography. Patients whom undergoing elective coronary angiography will fulfill the Beck Anxiety Inventory, Beck…
- Conditions
- Coronary Artery Disease, Coronary Artery Ectasia, Slow-Flow Phenomenon, Endothelial Dysfunction
- Trial name
- STRAIN-TIMI (NCT02831153)
- Testing
- coronary angiography
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 2,000 people
- Sponsor
- Ertan YETKIN
STEMI, Large Thrombus Burden
Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction
Angiographic no-reflow during primary PCI procedures occurs at relatively high rate (25%) and is associated with worsening of long term morbidity and mortality.
- Conditions
- STEMI, Large Thrombus Burden, No-Reflow Phenomenon
- Trial name
- UPFRONT-STEMI (NCT05393557)
- Testing
- Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury
- Volunteers
- 626 people
- Sponsor
- Cairo University
ST Elevation Myocardial Infarction, No-Reflow Phenomenon
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban.
- Trial name
- NCT07195812
- Testing
- Dual Antiplatelet (DAPT) Therapy, Rivaroxaban
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Myocardial Infarction, No Reflow Phenomenon
Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI
To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI.
- Trial name
- VaBiNoR (NCT07132489)
- Testing
- HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio
- Volunteers
- 114 people
- Sponsor
- Assiut University
No-Reflow Phenomenon, STEMI - ST Elevation Myocardial Infarction
NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction
The aim of this study is to investigate the association between NGAL plasma levels in ST-elevation myocardial infarction and the no-reflow phenomenon, adverse events during hospitalization and at 30-day follow-up.
- Trial name
- NCT03264859
- Testing
- NGAL levels early and post STEMI
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Myocardial Infarction, No-Reflow Phenomenon
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
The patients with acute myocardial infarction (AMI) present high mortality and morbidity rate,even treated with stenting in the blocked heart vessels. The appearance of no-reflow is common after re-opening of the blocked vessel.
- Trial name
- NCT02233790
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 600 people
- Sponsor
- First Hospital of China Medical University
No Reflow Phenomenon, STEMI
No Reflow Phenomenon Incidence and Predictors
Background No reflow phenomenon is described in up to 65% of patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction (STEMI).
- Trial name
- NORM-PPCI (NCT04017169)
- Testing
- No intervention as observational study
- Where
- United Kingdom
- Volunteers
- 176 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Coronary Angiography, Coronary Artery Disease
Assessment Of Total Coronary Circulation Time Using TIMI Frame Count Method (TCCT-TIMI)
The aim of this study is to evaluate and describe the total coronary circulation time (TCCT) by using TIMI frame count method in patients performed coronary angiography.
- Conditions
- Coronary Angiography, Coronary Artery Disease, Coronary Artery Ectasia, Slow-Flow Phenomenon
- Trial name
- TCCT-TIMI (NCT02818127)
- Testing
- coronary angiography
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 2,000 people
- Sponsor
- Vascular and Molecular Cardiology Society
Ischemia-reperfusion Injury, No-reflow
Intracoronary Administration of Glucocorticoids as a Treatment Method for No-Glucocorticoid Treatment for No-Reflow in STEMI
The goal of this clinical trial is to improve reperfusion therapy in STEMI patients with no-reflow phenomenon. Based on literature review and pathological studies, the investigators believe that myocardial ischemia-reperfusion…
- Trial name
- GCT-NR-STEMI (NCT06552442)
- Testing
- Methylprednisolone
- Where
- Ukraine
- Volunteers
- 10 people
- Sponsor
- Amosov National Institute of Cardiovascular Surgery
ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention
The EPIVER Randomized Controlled Trial
The trial aims to estimate the efficacy and safety of the intracoronary administration of adrenalin, verapamil, as well as their combination compared to standard treatment in patients with STEMI and refractory coronary no-reflow…
- Conditions
- ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention, No-Reflow Phenomenon
- Trial name
- EPIVER (NCT04573751)
- Testing
- Standard therapy, Epinephrine, Verapamil
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Acute Coronary Syndrome, No-Reflow Phenomenon
Adrenaline for the Treatment of No-Reflow in Normotensive Patients
No-reflow is defined as the lack of myocardial perfusion despite opening of the epicardial coronary vessels in the setting of percutaneous coronary intervention (PCI).
- Conditions
- Acute Coronary Syndrome, No-Reflow Phenomenon, Normotensive
- Trial name
- NCT04699110
- Testing
- Adrenaline, Adenosine
- Where
- Pakistan
- Volunteers
- 201 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Myocardial Infarction
Nitroprusside for Prevention of no-Reflow in Primary Angioplasty
In patients admitted with acute myocardial infarction, there is a total occlusion of a coronary artery. Even after emergency catheterization and angioplasty, in some patients, the resumed blood flow is suboptimal and impacts on…
- Trial name
- NCT00128791
- Testing
- Nitroprusside
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Soroka University Medical Center
Myocardial Infarction
THE LASER-AMI STUDY - Excimer Laser Versus Manual Thrombus Aspiration in Acute Myocardial Infarction
The occurrence of no-reflow phenomenon after recanalization of the infarct related artery in acute myocardial infarction is described in up to 40% of cases.
- Trial name
- LASER-AMI (NCT01826006)
- Testing
- Excimer laser, Manual Thrombus Aspiration
- Where
- Italy
- Volunteers
- 194 people
- Sponsor
- Catholic University of the Sacred Heart
STEMI, No-Reflow Phenomenon
Insulin Resistance and Its Association With no Reflow Phenomenon After Primary PCI in Type II Diabetic STEMI Patients.
To investigate the relationship between the TyG index, coronary lesion complexity assessed by the SYNTAX score, and the development of the no-reflow phenomenon in STEMI patients with T2DM.
- Conditions
- STEMI, No-Reflow Phenomenon, Diabetic Patient
- Trial name
- NCT07706335
- Testing
- PCI
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Reperfusion Injury, Myocardial
Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI
This study is a single-center, prospective controlled trial addressing effectiveness of empagliflozin on cardiac-renal injury in patients with STEMI.
- Trial name
- NCT03591991
- Testing
- Empagliflozin
- Volunteers
- 128 people
- Sponsor
- Chinese PLA General Hospital
No-Reflow Phenomenon
Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
Predicting no reflow in ppci of STEMI patients using mean platelet volume together with STEMI clinical risk scores
- Trial name
- NCT04785209
- Testing
- Mean platelet volume, lymphocyte number, STEMI clinical risk scores
- Where
- Egypt
- Volunteers
- 640 people
- Sponsor
- Assiut University
Myocardial Infarction, No-Reflow Phenomenon
Genetic Determinants of the Coronary Microvascular Obstruction in PCI
Myocardial infarction (MI) remains one of the most common causes of death. Percutaneous coronary intervention (PCI) is the main treatment option to restore blood flow through the infarction-related coronary artery (IRA) in MI…
- Trial name
- NCT05355532
- Testing
- different variants of SNPs that may be associated with the coronary microvascular obstruction development
- Where
- 2 sites in Russia
- Volunteers
- 80 people
- Sponsor
- Privolzhsky Research Medical University
Acute Myocardial Infarction, Percutaneous Coronary Intervention
Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction
The purpose of this study is to evaluate the efficacy of three different vasodilators including diltiazem, verapamil and nitroglycerin for reversal of no-reflow/slow-flow during direct percutaneous coronary intervention for acute…
- Trial name
- EDUCATE-AMI (NCT00712894)
- Testing
- Diltiazem, Verapamil, Nitroglycerin
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Fudan University